|
|
Article: SGX, Roche Partner To Use FAST To Discover Antivirals.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Entering the first major pharmaceutical deal for its Fragments of Active Structures drug discovery technology, Structural GenomiX formed an alliance with F. Hoffmann-La Roche Ltd. to discover new antiviral therapeutics.
Structural GenomiX (SGX) will be responsible for discovering small-molecule inhibitors that Roche will develop and commercialize on a worldwide basis.
"This really represents an important milestone for us in terms of demonstrating the viability of our fragment-based lead-generation technology, which we call FAST," said Stephen Burley, chief scientific officer for San Diego-based SGX.
In return for use of ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|